Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Jannsen Biotech extends its partnership with BTI on xB3!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Feb 01, 2023 10:36pm
216 Views
Post# 35261301

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Jannsen Biotech extends its partnership with BTI on xB3!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Jannsen Biotech extends its partnership with BTI on xB3!!
That Bioasis Tweet is almost verbatim from the press release 
 
My earlier post is consistent with what I've been posting all along. My concern tonight was my friend ronrydell's comments about the $750,000 and $350,000 being available and that the notes aren't payable until June. I'm not so sure about all that. I did make a mistake there. A final payment of $250,000 of the $750,000 is yet to come from Midatech on February 7. But that still doesn't quite match up with having only enough money until March. 
 
Shortly after I posted earlier, I got some obscene emails from a long time shareholder. It seems that he would rather that I keep things to myself, or even lie for his benefit. I try really hard to ask good questions that are based on what Bioasis is doing and saying. Bioasis can set the record straight about what "an event of default" means. Graeme can do that. I doubt that too many shareholders want to think that everything is swell and then have Lind surprise everybody by declaring "an event of default" at any time before June 30.
 
I think that everyone must be aware that immediate action by shareholders may be required after voting results are released on Friday. 
 
jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities